424B3424B3
Sep 8, 2026Final prospectus0001493152-26-041786
All companies
Trade Bioaffinity Technologies Inc
Bioaffinity Technologies Inc
BIAFPublic
PublicUnited States(Nasdaq)Best valuation $7.58M1 market
Public listing
Listed· Nasdaq· Listing market: United StatesListing date
Aug 24, 2026
Offer price
Not available
Shares offered
Not available
Offering proceeds
Not available
Sources: sec-harvest, sec-edgar, nasdaq
IPO Calendar · NasdaqIPO
BIAFPrice
$6.48
24h
+5.25%
Valuation
$7.58M
24h volume
$540.15K
Type
IPO
Trade Bioaffinity Technologies IncNow trading publicly. Buy via a broker — opens in a new tab.
IPO Calendar · updated 46m ago
Financials
UnprofitableFrom SEC filings, latest FY ending Dec 31, 2025 · CIK 0001712762.
Revenue · -34.18% YoY
$6.16M
Net income
-$14.91M
Gross margin
0.07%
Cash
$6.45M
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $6.16M | $9.36M | $2.53M | $4.8K | — |
| Gross profit | — | — | — | $4.34K | — |
| Operating income | -$10.57M | -$8.95M | -$7.97M | -$4.01M | -$2.21M |
| Net income | -$14.91M | -$9.04M | -$7.94M | -$8.15M | -$6.33M |
| R&D expense | $1.38M | $1.46M | $1.47M | $1.38M | $1.01M |
| Cash & equivalents | $6.45M | $1.11M | $2.82M | $11.41M | $1.36M |
| Total assets | $10.96M | $6.51M | $8.22M | $12.18M | $1.45M |
| Total liabilities | $3.68M | $3.91M | $3.37M | $1.14M | $13.2M |
| Shareholders' equity | $7.28M | $2.6M | $4.86M | $11.04M | -$15.79M |
About Bioaffinity Technologies Inc
Bioaffinity Technologies Inc is a healthcare and life-sciences company with a business profile centered on medical products, therapies, diagnostics, or health-related services.
What the company does
- Develops healthcare products, therapies, devices, or services where clinical evidence and regulatory execution are central to the business.
- Operates in a market shaped by product differentiation, development timelines, reimbursement or customer adoption, and disciplined capital allocation.
- Relies on technical, clinical, commercial, and operational teams to move products from development toward broader use.
Business profile
Bioaffinity Technologies Inc belongs to the healthcare and life-sciences market, where product evidence, regulatory pathways, customer adoption, and funding discipline shape long-term outcomes.
SEC IPO filings
Final prospectusEDGAR filings resolved from BIAF / CIK 0001712762.
Sep 4, 2026Effective9999999995-26-002900
424B4424B4
Jun 18, 2026Final prospectus0001493152-26-029206
Jun 16, 2026Effective9999999995-26-002028
S-1/AS-1/A
Jun 16, 2026Amended0001493152-26-028877
CORRESPfilename1.htm
Jun 12, 2026SEC correspondence0001493152-26-028534
S-1S-1
Jun 12, 2026Filed0001493152-26-028507
424B3424B3
May 14, 2026Final prospectus0001493152-26-023063
May 12, 2026Effective9999999995-26-001591
CORRESPfilename1.htm
May 11, 2026SEC correspondence0001493152-26-022162
UPLOADfilename1.pdf
May 7, 2026SEC correspondence0000000000-26-004704
UPLOADfilename1.pdf
May 7, 2026SEC correspondence0000000000-26-004703
Bioaffinity Technologies Inc IPO — frequently asked questions
- When did Bioaffinity Technologies Inc go public?
- Bioaffinity Technologies Inc completed its IPO on Aug 24, 2026 on Nasdaq under the ticker BIAF and now trades publicly.
- Can I buy Bioaffinity Technologies Inc stock?
- Yes — Bioaffinity Technologies Inc is publicly traded on Nasdaq as BIAF. You can follow its live price, valuation and post-IPO performance above.
- What is Bioaffinity Technologies Inc's valuation?
- Bioaffinity Technologies Inc's most recent valuation tracked here is $7.58M, derived from live market prices.